Isomorphic Labs es una empresa de Alphabet que utiliza un enfoque basado en IA para acelerar y reimaginar el proceso de descubrimiento de fármacos, con el objetivo de diseñar nuevos medicamentos y, en última instancia, resolver todas las enfermedades.
Por qué importa
API disponible
overview
Isomorphic Labs es una herramienta de descubrimiento de fármacos impulsada por IA desarrollada por Alphabet Inc. que permite a las empresas farmacéuticas y biomédicas diseñar nuevos medicamentos. Aprovecha el aprendizaje automático avanzado, incluida la tecnología AlphaFold, para predecir y generar formas y secuencias de proteínas a nivel atómico.
features
Isomorphic Labs emplea un motor unificado de diseño de fármacos con IA para acelerar y reimaginar el proceso de descubrimiento de fármacos, ofreciendo un conjunto de capacidades para el diseño molecular y la predicción de interacciones.
use cases
Isomorphic Labs se dirige principalmente a entidades y expertos involucrados en investigación y desarrollo farmacéutico avanzado, que buscan aprovechar la IA para un descubrimiento de fármacos acelerado y más preciso.
pricing
Isomorphic Labs opera con un modelo freemium para su tecnología central, específicamente con AlphaFold 3 disponible de forma gratuita para investigación no comercial. El acceso comercial al motor propietario de diseño de fármacos con IA de Isomorphic Labs y sus capacidades avanzadas se facilita principalmente a través de colaboraciones estratégicas de investigación multi-objetivo y asociaciones con empresas farmacéuticas y biomédicas, en lugar de niveles de suscripción públicos.
Herramientas similares
Isomorphic Labs se distingue en el panorama del descubrimiento de fármacos con IA por su herencia de DeepMind y su enfoque en la reducción de la dependencia del laboratorio húmedo mediante simulación computacional, contrastando con los enfoques variados de sus competidores.
Generate Biomedicines uses a generative AI platform to design novel protein therapeutics from scratch, focusing on a diverse range of therapeutic modalities.
Similar to Isomorphic Labs, Generate Biomedicines focuses on de novo protein design for drug discovery. Their platform emphasizes generating a broader spectrum of therapeutic modalities, whereas Isomorphic Labs explicitly mentions predicting and generating protein shapes and sequences. Pricing is likely enterprise-based, contrasting with Isomorphic Labs' stated freemium model.
Xaira Therapeutics integrates cutting-edge AI research, including technologies like RFdiffusion, with therapeutic development to design novel proteins and antibodies for complex biological challenges.
Like Isomorphic Labs, Xaira Therapeutics leverages advanced AI for protein and antibody design in drug discovery. Xaira appears to have a strong focus on integrating academic AI breakthroughs directly into therapeutic development, potentially offering a broader range of AI models for novel protein and antibody generation.
Latent Labs is building generative AI models for de novo protein design, with a focus on creating entirely new therapeutic molecules like antibodies and enzymes to make biology more programmable.
Latent Labs directly competes with Isomorphic Labs in the de novo protein design space, aiming to generate entirely new therapeutic molecules. Their approach emphasizes a predominantly digital workflow with wet lab validation, aligning with Isomorphic's AI-first strategy for drug discovery.
DenovAI offers an AI-driven platform, AlphaDesign, capable of creating new, functional synthetic proteins entirely de novo without requiring training on evolutionary data or using known protein templates.
DenovAI is a direct competitor to Isomorphic Labs, both aiming to design novel proteins from scratch using AI. DenovAI highlights its ability to generate synthetic proteins without evolutionary templates, potentially offering a distinct approach to sequence and structure generation compared to Isomorphic Labs' methods.
ProteinQure specializes in the AI-driven design of novel exotic peptides with broad therapeutic applications, leveraging its ProteinStudio™ computational platform for de novo peptide design and tissue-specific delivery.
ProteinQure, through its ProteinStudio™ platform, directly competes with Isomorphic Labs in AI-driven protein/peptide design for drug discovery. Its unique focus on exotic peptides and clinical-stage development for targeted delivery differentiates its therapeutic application, while Isomorphic Labs focuses more broadly on protein shapes and sequences.
AI Reputation Report
ChatGPT, Perplexity, Gemini, Claude & Grok answer buyer questions about Isomorphic Labs every day. See whether they name Isomorphic Labs — or send buyers to a rival.
